Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parkinson Disease Dementia Clear all
Completed Not applicable Interventional Results available

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

NCT00294554
View directory record Official record
Conditions
Parkinson's Disease, Cognitive Impairment, Dementia
Interventions
Memantine, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 3, 2026, 1:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biofluid Research on Age-Related or Inherited Neurodegeneration

NCT07798700
View directory record Official record
Conditions
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Fronto-temporal Lobar Dementia, Dementia With Lewy Bodies (DLB), Cortical Basal Syndrome (CBS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy(PSP), Parkinson's Disease (PD), Parkinson's Disease Dementia (PDD), Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Posterior Cortical Atrophy (PCA), Primary Lateral Sclerosis (PLS), Primary Muscular Atrophy (PMA)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2070
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 3, 2026, 1:24 PM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia

NCT03938922
View directory record Official record
Conditions
Parkinson Disease, Dementia
Interventions
Active Investigational Treatment ENT-01
Drug
Lead sponsor
Enterin Inc.
Industry
Eligibility
30 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Fresno, California • Toms River, New Jersey • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 3, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

NCT00970229
View directory record Official record
Conditions
Parkinson Disease, Huntington Disease
Interventions
[123I]MNI-420
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 3, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

NCT00612872
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease, Healthy Controls, Multiple Sclerosis
Interventions
[123I]CLINDE
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 3, 2026, 1:24 PM EDT
Completed Phase 4 Interventional Results available

The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

NCT00988117
View directory record Official record
Conditions
Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
Interventions
Rivastigmine Patch 9.5 cm2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 3, 2026, 1:24 PM EDT
Completed No phase listed Observational

Speech Accessibility Project

NCT05889260
View directory record Official record
Conditions
Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Dementia With Lewy Bodies
Interventions
Not listed
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Denver, Colorado • Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 3, 2026, 1:24 PM EDT
Active, not recruiting Not applicable Interventional

PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia

NCT06389032
View directory record Official record
Conditions
Lewy Body Dementia, Parkinson Disease Dementia, Dementia With Lewy Bodies, Lewy Body Disease
Interventions
Peer Mentor Support and Caregiver Education, Caregiver Education
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 3, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

NCT00623103
View directory record Official record
Conditions
Parkinson's Disease Dementia
Interventions
Rivastigmine capsule, Rivastigmine transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2011 · Synced Oct 3, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

NCT02702102
View directory record Official record
Conditions
Diffuse Lewy Body Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
Interventions
11C-PBR28
Drug
Lead sponsor
Columbia University
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 3, 2026, 1:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

NCT04396873
View directory record Official record
Conditions
Parkinson's Disease, Dementia, Alzheimer's Disease, ALS, Mild Cognitive Impairment
Interventions
11C-MC1, 11C-PS13, 18f-florbetaben
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 99 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 3, 2026, 1:24 PM EDT
Completed No phase listed Observational

P-glycoprotein Function in Brain Diseases

NCT00677885
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Frontotemporal Lobar Degeneration
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 3, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01028209
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
Interventions
[18F] PBR06
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 3, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 3, 2026, 1:24 PM EDT
Completed No phase listed Observational Results available

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

NCT03647137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Detailed motor testing, including FoG, in PD subjects
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 3, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

NCT04764669
View directory record Official record
Conditions
Lewy Body Disease, Parkinson Disease
Interventions
E2027
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Sun City, Arizona • Atlantis, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 3, 2026, 1:24 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

NCT07284290
View directory record Official record
Conditions
Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
Interventions
Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).
Procedure · Diagnostic Test · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
50 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 3, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

NCT03713957
View directory record Official record
Conditions
Parkinson Disease
Interventions
GRF6021, Placebo
Drug · Other
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Englewood, Colorado • Doral, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 3, 2026, 1:24 PM EDT
Terminated Not applicable Interventional Results available

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

NCT00745030
View directory record Official record
Conditions
REM Behavior Disorder, Parkinsonism
Interventions
Rozerem, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 3, 2026, 1:24 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease

NCT04148326
View directory record Official record
Conditions
Parkinson Disease, Parkinsons Disease With Dementia, Parkinson-Dementia Syndrome, Parkinson Disease 2, Parkinson Disease 3, Parkinson Disease 4
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 3, 2026, 1:24 PM EDT
Completed No phase listed Observational

Memory Disorders Registry

NCT00654563
View directory record Official record
Conditions
Dementia, Alzheimer's Disease, Parkinson Disease, Huntington Disease
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 3, 2026, 1:24 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 3, 2026, 1:24 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Mid-frontal Delta/Theta and Cognitive Control

NCT06984757
View directory record Official record
Conditions
Parkinson&Amp;Amp;#39;s Disease (PD)
Interventions
Deep-brain Stimulation, Transcranial Magnetic Stimulation, Transcranial Alternating Current Stimulation
Device
Lead sponsor
Nandakumar Narayanan
Other
Eligibility
18 Years to 99 Years
Enrollment
635 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2029
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 3, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

NCT03305809
View directory record Official record
Conditions
Lewy Body Dementia
Interventions
LY3154207, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years to 85 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 3, 2026, 1:24 PM EDT